Skip to main content
. 2022 Mar 17;6:16. doi: 10.1038/s41698-022-00260-0

Fig. 6. PDCs established from alectinib-failure patients showed high resistance to multiple ALK-TKIs but were vulnerable to GSK3 inhibition.

Fig. 6

Cell viability of ALK-positive cancer cell lines and PDCs treated with the indicated concentration of a alectinib and b lorlatinib for 72 h (n = 3) and c JFCR-028-5 and d JFCR-278 cells treated with the indicated concentration of lorlatinib with or without a fixed concentration of GSK3 inhibitors for 72 h (n = 3). Each point represents the mean ± SD of three replicates. Synergy distribution maps of e JFCR-028-5 and f JFCR-278 cells treated with the indicated concentration of lorlatinib in the absence or presence of the indicated concentration of LY2090314 for 24 h. Synergy scores were calculated using the ZIP model. The squares of white dots indicate areas with the highest ZIP synergy scores. e Evaluation of the effect on apoptosis of JFCR-028-5 cells treated with the of 30 nM lorlatinib and 100 nM LY2090314. Apoptosis was evaluated using Annexin-V and PI staining after 72 h of the indicated drug treatment. The apoptotic cells were shown in red square and the percentage of apoptotic cells is shown in red value.